Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports positive findings from phase III 4CMenB trial

Novartis reports positive findings from phase III 4CMenB trial

14th September 2010

Novartis has expressed confidence in the potentially groundbreaking nature of its new multicomponent meningococcal serogroup B vaccine 4CMenB, based on positive data from a clinical trial.

According to results from the phase III study, which involved more than 3,600 infants, a majority of patients experienced a "robust" immune response against all vaccine meningococcal B antigens when using the drug.

Moreover, the treatment was also shown to demonstrate an acceptable tolerability profile when co-administered with other standard infant vaccines, meaning it could be potentially used within the first year of life.

Novartis states that this could make 4CMenB the first broad-coverage vaccine to be developed against meningococcal B disease, which can often lead to death within 24 hours of the first symptoms appearing.

Andrin Oswald, head of Novartis' vaccines and diagnostics division, said: "The challenge with MenB is that there are thousands of circulating strains and developing a broadly protective vaccine has, until now, been difficult."

Earlier this week, Novartis announced that it has received its first regulatory approval in Russia for Gilenya, an innovative oral tablet-based treatment for multiple sclerosis.ADNFCR-8000103-ID-800063538-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.